Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Dr. Reddy’s expansion plans for API production
Unrelated to the inspection of
the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe
The future of API manufacturing at Dr. Reddy’s
Almost immediately after our analysis on why “Dr. Reddy’s largest API facility maybe the
